Skip to content
10-Q

Quarterly Report

MoonLake Immunotherapeutics MLTX

0001821586-26-000007

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 73.62M sh
Shares Diluted Q1 2026 · Mar 31, 2026 71.27M sh
Shares Diluted Q1 2026 · Mar 31, 2025 63.23M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $35K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$66.29M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$38.14M
Long Term Debt Q1 2026 · Mar 31, 2026 $99.02M
Long Term Debt Q1 2026 · Dec 31, 2025 $74.1M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $298.49M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $334.52M
Stockholders Equity Q1 2026 · Mar 31, 2026 $254.02M
Stockholders Equity Q1 2026 · Dec 31, 2025 $304.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $46.11M
Current Liabilities Q1 2026 · Dec 31, 2025 $45.48M
Total Liabilities Q1 2026 · Mar 31, 2026 $146.35M
Total Liabilities Q1 2026 · Dec 31, 2025 $119.95M
Current Assets Q1 2026 · Mar 31, 2026 $396.64M
Current Assets Q1 2026 · Dec 31, 2025 $421.69M
Total Assets Q1 2026 · Mar 31, 2026 $400.37M
Total Assets Q1 2026 · Dec 31, 2025 $424.43M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.98
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.63
Eps Basic Q1 2026 · Mar 31, 2026 −$0.98
Eps Basic Q1 2026 · Mar 31, 2025 −$0.63
Sga Expense Q1 2026 · Mar 31, 2026 $15.51M
Sga Expense Q1 2026 · Mar 31, 2025 $11.03M
Rd Expense Q1 2026 · Mar 31, 2026 $54.52M
Rd Expense Q1 2026 · Mar 31, 2025 $36.46M
Net Income Q1 2026 · Mar 31, 2026 −$69.71M
Net Income Q1 2026 · Mar 31, 2025 −$39.94M
Operating Income Q1 2026 · Mar 31, 2026 −$70.02M
Operating Income Q1 2026 · Mar 31, 2025 −$47.49M